0001209191-19-056713.txt : 20191115
0001209191-19-056713.hdr.sgml : 20191115
20191115160719
ACCESSION NUMBER: 0001209191-19-056713
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191113
FILED AS OF DATE: 20191115
DATE AS OF CHANGE: 20191115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tatsis Ourania
CENTRAL INDEX KEY: 0001789815
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 191224567
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS, INC.
STREET 2: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-11-13
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001789815
Tatsis Ourania
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
SVP, CRO
Common Stock
2019-11-13
4
M
0
2853
155.57
A
10105
D
Common Stock
2019-11-13
4
S
0
2853
205.59
D
7252
D
Stock Option (Right to Buy)
155.57
2019-11-13
4
M
0
2853
0.00
D
2028-02-05
Common Stock
2853
3669
D
Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1.
Open market sales reported on this line occurred at a weighted average price of $205.59 (range $205.57 to $205.76).
Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
The option vests in 16 quarterly installments from 2/6/2018.
/s/ Omar White, Attorney-in-Fact
2019-11-15